Acquired immunodeficiencies and tuberculosis: Focus on HIV/AIDS and diabetes mellitus

Immunological Reviews

Volumn 264, Issue 1, 2015, Pages 121-137

  Ronacher, Katharina ^a   Joosten, Simone A ^b   van Crevel, Reinout ^c   Dockrell, Hazel M ^d   Walzl, Gerhard ^a   Ottenhoff, Tom H M ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

HIV; Tuberculosis; Type II diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; COMPLEMENT RECEPTOR; GAMMA INTERFERON; GLIBENCLAMIDE; GLUTATHIONE; HEMOGLOBIN A1C; INTERLEUKIN 17; INTERLEUKIN 18; METFORMIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; COMORBIDITY; CYTOKINE PRODUCTION; DIABETIC PATIENT; GENETIC RISK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MIXED INFECTION; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH17 CELL; TH22 CELL; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADVERSE EFFECTS; COMMUNICABLE DISEASE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PATHOGEN INTERACTION; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; COINFECTION; COMMUNICABLE DISEASES, EMERGING; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; TUBERCULOSIS;

EID: 84923208538     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12257     Document Type: Article

References (194)

1. McGrath M, Gey van Pittius NC, van Helden PD, Warren RM, Warner DF. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2014;69:292-302.
2. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2014;44:617-626.
3. Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract 2014; doi: 10.1016/j.diabres.2014.06.011. [Epub ahead of print].
4. Murray CJ, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:1005-1070.
5. Lai RP, Nakiwala JK, Meintjes G, Wilkinson RJ. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2013;43:1995-2002.
6. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health 2010;15:1289-1299.
7. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. 2013. International Diabetes Federation, Brussels, Belgium. Available from http://www.idf.org/diabetesatlas.
8. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.
9. Lonnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2014;2:730-739.
10. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007;30:113-119.
11. Larson R, Capili B, Eckert-Norton M, Colagreco JP, Anastasi JK. Disorders of glucose metabolism in the context of human immunodeficiency virus infection. J Am Acad Nurse Pract 2006;18:92-103.
12. Oni T, Stoever K, Wilkinson RJ. Tuberculosis, HIV, and type 2 diabetes mellitus: a neglected priority. Lancet Respir Med 2013;1:356-358.
13. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009;80:634-639.
14. Chiang CY, et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. PLoS ONE 2014;9:e93397.
15. Riza AL, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol 2014;2:740-753.
16. Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012;20:419-428.
17. Srivastava S, Ernst JD. Cell-to-cell transfer of M. tuberculosis antigens optimizes CD4 T cell priming. Cell Host Microbe 2014;15:741-752.
18. Geldmacher C, Zumla A, Hoelscher M. Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS 2012;7:268-275.
19. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011;25:549-567.
20. Shim TS. Diagnosis and treatment of latent tuberculosis infection due to initiation of anti-TNF therapy. Tuberc Respir Dis 2014;76:261-268.
21. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993;178:2243-2247.
22. van de Vosse E, van Dissel JT, Ottenhoff TH. Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis 2009;9:688-698.
23. Gallegos AM, van Heijst JW, Samstein M, Su X, Pamer EG, Glickman MS. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011;7:e1002052.
24. Beveridge NE, et al. A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis 2008;88:631-640.
25. Hanekom WA, et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 2008;5:e145.
26. Tameris M, et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS ONE 2014;9:e87340.
27. Tameris MD, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-1028.
28. Lindenstrom T, Aagaard C, Christensen D, Agger EM, Andersen P. High-frequency vaccine-induced CD8(+) T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection. Eur J Immunol 2014;44:1699-1709.
29. Darrah PA, et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol 2014;193:1799-1811.
30. Kagina BM, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010;182:1073-1079.
31. Darrah PA, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-850.
32. Forbes EK, et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008;181:4955-4964.
33. Lindenstrom T, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009;182:8047-8055.
34. + T cells in adults. Am J Respir Crit Care Med 2010;181:1407-1417.
35. + T cells. Eur J Immunol 2010;40:279-290.
36. + memory T lymphocyte populations. Eur J Immunol 2007;37:3089-3100.
37. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009;39:723-729.
38. Caccamo N, et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010;40:2211-2220.
39. Day CL, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 2011;187:2222-2232.
40. Walker NF, Meintjes G, Wilkinson RJ. HIV-1 and the immune response to TB. Future Virol 2013;8:57-80.
41. de Noronha AL, Bafica A, Nogueira L, Barral A, Barral-Netto M. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol Res Pract 2008;204:155-161.
42. Shen JY, Barnes PF, Rea TH, Meyer PR. Immunohistology of tuberculous adenitis in symptomatic HIV infection. Clin Exp Immunol 1988;72:186-189.
43. Nambuya A, Sewankambo N, Mugerwa J, Goodgame R, Lucas S. Tuberculous lymphadenitis associated with human immunodeficiency virus (HIV) in Uganda. J Clin Pathol 1988;41:93-96.
44. Chiacchio T, et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J Infect 2014;69:533-545.
45. Sutherland JS, et al. Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J Immunol 2010;184:6537-6544.
46. Mansoor N, et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 2009;199:982-990.
47. Kalsdorf B, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009;180:1262-1270.
48. Ottenhoff TH. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int J Tuberc Lung Dis 2012;16:1424-1432.
49. Finke JS, Shodell M, Shah K, Siegal FP, Steinman RM. Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol 2004;24:647-652.
50. Van den Bergh R, Vanham G, Raes G, De Baetselier P, Colebunders R. Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis 2006;6:2-3.
51. Anandaiah A, et al. Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced Toll-like receptor signaling pathway in vitro. Infect Immun 2013;81:2-10.
52. Joosten SA, Ottenhoff TH. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol 2008;69:760-770.
53. Boussiotis VA, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317-1325.
54. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006;173:803-810.
55. + T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 2006;144:25-34.
56. + regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 2007;104:8029-8034.
57. Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SA. CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells. Eur J Immunol 2013;43:1925-1932.
58. + T cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cells. PLoS ONE 2014;9:e94192.
59. Joosten SA, et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog 2010;6:e1000782.
60. Chen X, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 2007;123:50-59.
61. Herzmann C, et al. Increased frequencies of pulmonary regulatory T-cells in latent Mycobacterium tuberculosis infection. Eur Respir J 2012;40:1450-1457.
62. Hougardy JM, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 2007;176:409-416.
63. Scott-Browne JP, et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 2007;204:2159-2169.
64. Kursar M, et al. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol 2007;178:2661-2665.
65. Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis 2013;208:739-748.
66. Cai B, et al. Micro-inflammation characterized by disturbed Treg/Teff balance with increasing sIL-2R in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2013;121:214-219.
67. Zeng C, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med 2012;90:175-186.
68. Singh A, Vajpayee M, Ali SA, Chauhan NK. Cellular interplay among Th17, Th1, and Treg cells in HIV-1 subtype "C" infection. J Med Virol 2014;86:372-384.
69. Li D, et al. Loss of balance between T helper type 17 and regulatory T cells in chronic human immunodeficiency virus infection. Clin Exp Immunol 2011;165:363-371.
70. Menart-Houtermans B, et al. Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: results from the German diabetes study (GDS). Diabetes Care 2014;37:2326-2333.
71. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-377.
72. Gopal R, et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 2014;10:e1004099.
73. Cruz A, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010;207:1609-1616.
74. Wareham AS, Tree JA, Marsh PD, Butcher PD, Dennis M, Sharpe SA. Evidence for a role for interleukin-17, Th17 cells and iron homeostasis in protective immunity against tuberculosis in cynomolgus macaques. PLoS ONE 2014;9:e88149.
75. + T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008;180:1962-1970.
76. Matthews K, et al. Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis 2011;91:587-593.
77. Commandeur S, et al. Double- and monofunctional CD4(+) and CD8(+) T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol 2011;41:2925-2936.
78. + T cells in human tuberculosis. J Immunol 2011;186:1068-1080.
79. Nyendak MR, et al. Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment. PLoS ONE 2013;8:e81564.
80. Caccamo N, et al. Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 2009;4:e5528.
81. Day CL, et al. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. PLoS ONE 2014;9:e94949.
82. + cytolytic T cells in human tuberculosis and HIV infection. Biochem Biophys Res Commun 2010;396:50-57.
83. Chen CY, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009;5:e1000392.
84. Mazzaccaro RJ, et al. Cytotoxic T lymphocytes in resistance to tuberculosis. Adv Exp Med Biol 1998;452:85-101.
85. De Libero G, Mori L. The T-cell response to lipid antigens of Mycobacterium tuberculosis. Front Immunol 2014;5:219.
86. + CTLs in Mycobacterium tuberculosis-infected humans. J Immunol 2008;180:3436-3446.
87. Zhang Q, Xiao HP, Cui HY, Sugawara I. Significant increase in natural-killer T cells in patients with tuberculosis complicated by type 2 diabetes mellitus. J Int Med Res 2011;39:105-111.
88. Cohen GB, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-671.
89. Gold MC, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010;8:e1000407.
90. Le Bourhis L, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 2010;11:701-708.
91. Kjer-Nielsen L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012;491:717-723.
92. Harriff MJ, et al. Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8(+) T cells. PLoS ONE 2014;9:e97515.
93. Gold MC, et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J Exp Med 2014;211:1601-1610.
94. + mucosal associated invariant T (MAIT) cells are found in HIV and HIV/TB co-infection. PLoS ONE 2013;8:e83474.
95. Joosten SA, Fletcher HA, Ottenhoff TH. A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. PLoS ONE 2013;8:e73230.
96. Cliff JM, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013;207:18-29.
97. Ulrichs T, et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004;204:217-228.
98. Kozakiewicz L, Phuah J, Flynn J, Chan J. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Adv Exp Med Biol 2013;783:225-250.
99. Phuah JY, Mattila JT, Lin PL, Flynn JL. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am J Pathol 2012;181:508-514.
100. Zhang M, et al. CD19(+)CD1d(+)CD5(+) B cell frequencies are increased in patients with tuberculosis and suppress Th17 responses. Cell Immunol 2012;274:89-97.
101. Zhang M, et al. Anti-tuberculosis treatment enhances the production of IL-22 through reducing the frequencies of regulatory B cell. Tuberculosis 2014;94:238-244.
102. Kozakiewicz L, et al. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog 2013;9:e1003472.
103. Lowe DM, Redford PS, Wilkinson RJ, O'Garra A, Martineau AR. Neutrophils in tuberculosis: friend or foe? Trends Immunol 2012;33:14-25.
104. Torrado E, et al. Differential and site specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse. PLoS ONE 2013;8:e61681.
105. Tomlinson GS, et al. HIV-1 infection of macrophages dysregulates innate immune responses to Mycobacterium tuberculosis by inhibition of interleukin-10. J Infect Dis 2014;209:1055-1065.
106. Kumawat K, Pathak SK, Spetz AL, Kundu M, Basu J. Exogenous Nef is an inhibitor of Mycobacterium tuberculosis-induced tumor necrosis factor-alpha production and macrophage apoptosis. J Biol Chem 2010;285:12629-12637.
107. Killian MS. Dual role of autophagy in HIV-1 replication and pathogenesis. AIDS Res Ther 2012;9:16.
108. Gray JM, Cohn DL. Tuberculosis and HIV coinfection. Semin Respir Crit Care Med 2013;34:32-43.
109. Viswanathan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS ONE 2012;7:e41367.
110. Tack CJ, Stienstra R, Joosten LA, Netea MG. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev 2012;249:239-252.
111. Neyrolles O, et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS ONE 2006;1:e43.
112. Hand WL, Hand DL, Vasquez Y. Increased polymorphonuclear leukocyte respiratory burst function in type 2 diabetes. Diabetes Res Clin Pract 2007;76:44-50.
113. Ferracini M, Martins JO, Campos MR, Anger DB, Jancar S. Impaired phagocytosis by alveolar macrophages from diabetic rats is related to the deficient coupling of LTs to the Fc gamma R signaling cascade. Mol Immunol 2010;47:1974-1980.
114. Lecube A, Pachon G, Petriz J, Hernandez C, Simo R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLoS ONE 2011;6:e23366.
115. Li P, et al. Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J Biol Chem 2010;285:15333-15345.
116. Gomez DI, Twahirwa M, Schlesinger LS, Restrepo BI. Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control. Tuberculosis 2013;93:192-197.
117. Restrepo BI, Twahirwa M, Rahbar MH, Schlesinger LS. Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLoS ONE 2014;9:e92977.
118. Zilverschoon GR, Tack CJ, Joosten LA, Kullberg BJ, van der Meer JW, Netea MG. Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. Int J Obes (Lond) 2008;32:1407-1414.
119. Stew SS, Martinez PJ, Schlesinger LS, Restrepo BI. Differential expression of monocyte surface markers among TB patients with diabetes co-morbidity. Tuberculosis 2013;93(Suppl):S78-S82.
120. Wang CH, Yu CT, Lin HC, Liu CY, Kuo HP. Hypodense alveolar macrophages in patients with diabetes mellitus and active pulmonary tuberculosis. Tuber Lung Dis 1999;79:235-242.
121. Sugawara I, Mizuno S. Higher susceptibility of type 1 diabetic rats to Mycobacterium tuberculosis infection. Tohoku J Exp Med 2008;216:363-370.
122. Marhoffer W, Stein M, Schleinkofer L, Federlin K. Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus. Diabetes Res Clin Pract 1993;19:183-188.
123. Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M, Lertmemongkolchai G. Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 2009;77:456-463.
124. Surendar J, Mohan V, Pavankumar N, Babu S, Aravindhan V. Increased levels of serum granulocyte-macrophage colony-stimulating factor is associated with activated peripheral dendritic cells in type 2 diabetes subjects (CURES-99). Diabetes Technol Ther 2012;14:344-349.
125. Musilli C, et al. Characterization of circulating and monocyte-derived dendritic cells in obese and diabetic patients. Mol Immunol 2011;49:234-238.
126. Kumar NP, George PJ, Kumaran P, Dolla CK, Nutman TB, Babu S. Diminished systemic and antigen-specific type 1, type 17, and other proinflammatory cytokines in diabetic and prediabetic individuals with latent Mycobacterium tuberculosis infection. J Infect Dis 2014;210:1670-1678.
127. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch immunol Ther Exp 2013;61:119-125.
128. Kumar NP, et al. Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines. Ann Am Thorac Soc 2013;10:441-449.
129. Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol 2007;37:518-524.
130. Podell BK, et al. Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity. Am J Pathol 2014;184:1104-1118.
131. Jagannathan-Bogdan M, et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 2011;186:1162-1172.
132. Dhiman R, Venkatasubramanian S, Paidipally P, Barnes PF, Tvinnereim A, Vankayalapati R. Interleukin 22 inhibits intracellular growth of Mycobacterium tuberculosis by enhancing calgranulin A expression. J Infect Dis 2014;209:578-587.
133. Gan SH, et al. Interferon-gamma responses to Mycobacterium tuberculosis-specific antigens in diabetes mellitus. Eur Respir J 2014;44:805-808.
134. Faurholt-Jepsen D, et al. Diabetes is associated with lower tuberculosis antigen-specific interferon gamma release in Tanzanian tuberculosis patients and non-tuberculosis controls. Scand J Infect Dis 2014;46:384-391.
135. Walsh MC, et al. The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis 2011;15:179-184, i-iii.
136. Stalenhoef JE, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008;27:97-103.
137. Restrepo BI, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008;47:634-641.
138. +CD127- T-cells in patients with pulmonary tuberculosis and diabetes mellitus. Respirology 2012;17:876-882.
139. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-977.
140. Maertzdorf J, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011;12:15-22.
141. Maertzdorf J, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012;109:7853-7858.
142. Maertzdorf J, et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 2011;6:e26938.
143. Ottenhoff TH, et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 2012;7:e45839.
144. Mistry R, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007;195:357-365.
145. Jacobsen M, et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 2007;85:613-621.
146. Anderson ST, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 2014;370:1712-1723.
147. Kaforou M, et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med 2013;10:e1001538.
148. van Crevel R, Dockrell HM, TANDEM Consortium. TANDEM: understanding diabetes and tuberculosis. Lancet Diabetes Endocrinol 2014;2:270-272.
149. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-589.
150. Cho YS, et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet 2012;44:67-72.
151. Replication DIG, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 2014;46:234-244.
152. Consortium STD, et al. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature 2014;506:97-101.
153. Moltke I, et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 2014;512:190-193.
154. Kuijl C, et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 2007;450:725-730.
155. Thye T, et al. Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11 2. Nat Genet 2010;42:739-741.
156. Thye T, et al. Common variants at 11p13 are associated with susceptibility to tuberculosis. Nat Genet 2012;44:257-259.
157. Png E, et al. A genome wide association study of pulmonary tuberculosis susceptibility in Indonesians. BMC Med Genet 2012;13:5.
158. Chimusa ER, et al. Genome-wide association study of ancestry-specific TB risk in the South African Coloured population. Hum Mol Genet 2014;23:796-809.
159. Wang X, et al. Association of polymorphisms in the Chr18q11 2 locus with tuberculosis in Chinese population. Hum Genet 2013;132:691-695.
160. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002;20:581-620.
161. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis 2005;85:53-64.
162. Tobin DM, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010;140:717-730.
163. Davila S, et al. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet 2008;4:e1000218.
164. Intemann CD, et al. Autophagy gene variant IRGM -261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS Pathog 2009;5:e1000577.
165. van Crevel R, et al. Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. J Infect Dis 2009;200:1671-1674.
166. Caws M, et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008;4:e1000034.
167. Coussens AK, Martineau AR, Wilkinson RJ. Anti-inflammatory and antimicrobial actions of vitamin D in combating TB/HIV. Scientifica 2014;2014:903680.
168. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 2012;8:e1002689.
169. Badawi A, Sayegh S, Sadoun E, Al-Thani M, Arora P, Haddad PS. Relationship between insulin resistance and plasma vitamin D in adults. Diabetes Metabol Syndr Obes 2014;7:297-303.
170. Lopez-Lopez N, et al. Vitamin D supplementation promotes macrophages anti-mycobacterial activity in type 2 diabetes mellitus patients with low vitamin D receptor expression. Microbes Infect 2014;16:755-761.
171. Fabri M, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011;3:104ra102.
172. Salamon H, et al. Cutting edge: vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. J Immunol 2014;193:30-34.
173. Gan YH. Host susceptibility factors to bacterial infections in type 2 diabetes. PLoS Pathog 2013;9:e1003794.
174. Collison KS, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002;71:433-444.
175. Tan KS, et al. Glutathione deficiency in type 2 diabetes impairs cytokine responses and control of intracellular bacteria. J Clin Invest 2012;122:2289-2300.
176. Koh GC, et al. Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling. PLoS ONE 2013;8:e54961.
177. Millman AC, Salman M, Dayaram YK, Connell ND, Venketaraman V. Natural killer cells, glutathione, cytokines, and innate immunity against Mycobacterium tuberculosis. J Interferon Cytokine Res 2008;28:153-165.
178. Lamkanfi M, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009;187:61-70.
179. Kewcharoenwong C, et al. Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. Sci Rep 2013;3:3363.
180. Park DW, et al. Activation of AMPK enhances neutrophil chemotaxis and bacterial killing. Mol Med 2013;19:387-398.
181. Singhal A, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med 2014;6:263ra159.
182. Baker MA, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011;9:81.
183. World Health Organization. Collaborative Framework for Care and Control of Tuberculosis and Diabetes. 2011. Available from http://whqlibdocwhoint/publications/2011/9789241502252_engpdf.
184. India Diabetes Mellitus-Tuberculosis Study G. Screening of patients with diabetes mellitus for tuberculosis in India. Trop Med Int Health 2013;18:646-654.
185. Lin Y, et al. Screening patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health 2012;17:1302-1308.
186. Maertzdorf J, Weiner J 3rd, Kaufmann SH. Enabling biomarkers for tuberculosis control. Int J Tuber Lung Dis 2012;16:1140-1148.
187. Kaufmann SH, Dorhoi A. Inflammation in tuberculosis: interactions, imbalances and interventions. Curr Opin Immunol 2013;25:441-449.
188. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity 2013;38:633-643.
189. Suhre K. Metabolic profiling in diabetes. J Endocrinol 2014;221:R75-R85.
190. Bergman RN, Stefanovski D, Kim SP. Systems analysis and the prediction and prevention of Type 2 diabetes mellitus. Curr Opin Biotechnol 2014;28C:165-170.
191. Casey J, Sturm C Jr. Impaired response of lymphocytes from non-insulin-dependent diabetics to staphage lysate and tetanus antigen. J Clin Microbiol 1982;15:109-114.
192. Mathews CE, et al. Impaired function of antibodies to pneumococcal surface protein A but not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus. Clin Vaccine Immunol 2012;19:1360-1369.
193. Frasca D, et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine 2013;31:3603-3610.
194. Vallerskog T, Martens GW, Kornfeld H. Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J Immunol 2010;184:6275-6282.